查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2094109

臨床試驗影像市場－2026-2032年全球市場預測

Clinical Trial Imaging Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，臨床影像市場將成長至 28.3 億美元，複合年成長率為 8.42%。

主要市場統計數據
基準年 2025 16.1億美元
預計年份：2026年 17.2億美元
預測年份：2032年 28.3億美元
複合年成長率 (%) 8.42%

臨床試驗影像在腫瘤學、神經病學、循環系統疾病、肌肉骨骼疾病、罕見疾病以及先進療法的研發中，正日益成為證據生成的核心。隨著臨床試驗日益分散化、生物標記主導和全球化，影像技術擴大被用於支持患者篩檢、入組合格評估、終點評估、安全性監測、治療反應評估以及監管申報。磁振造影（MRI）、電腦斷層掃描（CT）、正子斷層掃描（PET）、單光子超音波電腦斷層掃描（SPECT）、超音波、光學成像和數位病理學等影像技術正與標準化的影像方案、集中式影像審查和定量成像相結合，以提高試驗的可重複性並降低試驗中心間的差異。

目前臨床試驗影像學的發展現狀受到以下因素的影響：方案複雜性的增加、影像生物標記應用的不斷擴展、對真實世界數據和縱向證據日益成長的需求，以及在多中心、跨國研究中協調影像工作流程的必要性。隨著監管機構對可追溯性、可審計性、影像品管、放射科醫生培訓和終點一致性的要求不斷提高，影像操作在試驗設計中的作用變得愈發關鍵。隨著申辦方尋求更快、更可靠的臨床開發途徑，影像學正從單純的輔助診斷工具轉變為貫穿整個研發生命週期、能夠增強決策的策略性臨床試驗資產。

臨床試驗影像技術的變革性變化

在精準醫療、數位化試驗基礎設施和複雜治療研究拓展的推動下，臨床試驗影像學領域正經歷一場變革。影像學終點指標正日益融入適應性試驗設計、籃式試驗、傘式試驗和標靶治療研究中，尤其是在解剖、功能或分子影像有助於識別患者亞群和量化治療反應的情況下。在腫瘤學領域，標準化的療效評估標準和病灶測量流程仍然至關重要，但神經退化性疾病的研究越來越依賴使用容積磁振造影（MRI）、澱粉樣蛋白和Tau白正子斷層掃描（PET）以及其他生物標記的影像學方法。

人工智慧在臨床試驗成像中的累積影響

人工智慧 (AI) 透過提高整個影像工作流程的效率、一致性和分析深度，對臨床試驗中的影像技術產生了累積的影響。 AI 工具正被應用於影像品質評估、器官和病灶分割、解剖抗蝕劑、放射組學特徵提取、工作流程優先排序、缺失資料檢測以及隨時間變化的分析。這些應用減輕了人工操作的負擔，支援標準化測量，並有助於識別僅憑傳統視覺判讀無法發現的影像模式。

臨床試驗影像學的關鍵區域見解

在亞太地區，臨床研究活動的拓展、醫院基礎設施的完善以及先進診斷技術的普及，正不斷提升臨床試驗影像領域在中國、印度、日本、韓國、澳洲和東南亞等國家和地區的重要性。該地區受益大規模的患者群體、疾病的多樣性以及對腫瘤學、循環系統和神經病學研究的持續投入。由於亞太地區各市場在設施能力、掃描儀可用性、認證等級和資料傳輸基礎設施等方面存在顯著差異，因此在影像操作中，通常需要進行嚴格的方案協調。

臨床試驗影像學的關鍵小組見解

隨著東南亞各國推動醫療保健現代化、癌症治療以及對數位研究基礎設施的投資，東協正日益成為臨床試驗影像領域的重要區域。儘管該地區擁有豐富的患者群體和經驗豐富的臨床實驗研究員，但影像操作仍需應對掃描儀規格、設施認證、放射科人員配備以及跨境資料管理實踐等方面的差異。

臨床試驗成像的關鍵國家見解

美國是臨床試驗影像學領域的領先中心，這得益於其龐大的學術研究網路、先進的放射學和核子醫學基礎設施，以及在監管申報（包括影像學終點）方面的豐富經驗。加拿大擁有健全的臨床研究管治、高品質的醫院系統，以及在腫瘤學、神經病學和心血管影像學方面的專業知識。墨西哥憑藉其大規模都市區醫療中心、不斷提升的研究能力，以及接觸到此前未接受過治療的患者和多樣化患者群體的機會，正在多國臨床試驗中嶄露頭角。

影像管理人員的實用建議

產業領導者應從臨床試驗設計的早期階段就將影像策略納入考量，而非僅將其視為下游操作環節。早期規劃階段應明確定義適當的影像終點、影像模式選擇、影像參數、解讀模型、標準、品管流程以及與臨床目標的統計一致性。影像方案必須清晰明確、切實可行，並符合監管要求。

臨床試驗中使用的成像調查方法

臨床試驗中影像學調查方法應結合二手資料研究、專家檢驗、監管審查和結構化定性評估。二手資料研究應包括同行評審的醫學文獻、臨床試驗註冊資料庫、監管指導文件、公共衛生出版刊物、影像學會標準、臨床終點標準以及關於影像技術應用、試驗設計實踐和治療領域發展趨勢的公開資訊。

結論：影像學作為策略證據引擎

臨床試驗影像在現代藥物和醫療設備研發中扮演著日益重要的角色，它支持對複雜治療領域進行客觀評估、生物標記發現、病患分層和時間序列監測。這一領域正透過標準化的影像方案、集中審核、數位影像交換、定量分析和人工智慧驅動的工作流程不斷進步。這些功能提高了數據的一致性，並幫助臨床團隊在全球試驗網路中產生更可靠的證據。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：臨床試驗影像市場：依產品/服務分類

  • 服務
    • 營運影像服務
    • 影像解讀與分析服務
    • 系統和技術支援服務
    • 測試設計和諮詢服務
  • 軟體
  • 硬體

第8章 臨床試驗影像市場：依影像方式分類

  • 電腦斷層掃描
  • 超音波心臟檢查
  • 磁振造影
  • 正子斷層掃描
  • 超音波
  • X光

第9章：臨床試驗影像市場：依最終使用者分類

  • 學術和政府附屬研究機構
  • 生技公司
  • 受託研究機構
  • 製藥公司

第10章：臨床試驗影像市場：依治療領域分類

  • 內分泌學
  • 免疫系統疾病
  • 感染疾病
  • 神經病學
  • 腫瘤學

第11章 臨床試驗影像市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第12章 臨床試驗影像市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章 臨床試驗影像市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第15章：公司簡介

  • Alimentiv Inc.
  • Anagram 4 Clinical Trials
  • Biospective Inc.
  • BioTelemetry, Inc.
  • Boston Imaging Core Lab LLC
  • Cardiovascular Imaging Technologies LLC
  • Clario
  • GE HealthCare Technologies Inc.
  • Icon PLC
  • Image Analysis Ltd
  • Image Core Lab Private Limited
  • Imaging Endpoints II LLC
  • Invicro, LLC
  • Ixico PLC
  • Median Technologies
  • Medical Metrics Inc. by Catalent, Inc.
  • Medidata by Dassault Systemes
  • Medpace, Inc.
  • Micron Inc.
  • Mint Medical GmbH
  • Navitas Life Sciences
  • Parexel International Corporation
  • Perceptive Informatics LLC
  • Perspectum Ltd
  • Prism Clinical Imaging, Inc.
  • ProScan Imaging LLC
  • Quotient Sciences Limited
  • Radiant Sage LLC
  • Resonance Health Ltd.
  • Voiant Clinical
  • WCG Clinical, Inc.
Product Code: MRR-501246435DF5

The Clinical Trial Imaging Market is projected to grow by USD 2.83 billion at a CAGR of 8.42% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.61 billion
Estimated Year [2026] USD 1.72 billion
Forecast Year [2032] USD 2.83 billion
CAGR (%) 8.42%

Clinical trial imaging has become a core enabler of evidence generation across oncology, neurology, cardiology, musculoskeletal disorders, rare diseases, and advanced therapy development. As clinical trials become more decentralized, biomarker-driven, and globally distributed, imaging is increasingly used to support patient screening, eligibility confirmation, endpoint assessment, safety monitoring, treatment response evaluation, and regulatory submissions. Modalities such as MRI, CT, PET, SPECT, ultrasound, optical imaging, and digital pathology are being integrated with standardized acquisition protocols, centralized image review, and quantitative image analysis to improve reproducibility and reduce variability across trial sites.

The clinical trial imaging landscape is shaped by rising protocol complexity, increased use of imaging biomarkers, growing demand for real-world and longitudinal evidence, and the need to harmonize imaging workflows across multicenter and multinational studies. Regulatory expectations for traceability, auditability, image quality control, reader training, and endpoint consistency continue to elevate the role of imaging operations in trial design. As sponsors pursue faster and more reliable clinical development pathways, imaging is shifting from a supportive diagnostic tool to a strategic clinical trial asset that strengthens decision-making throughout the development lifecycle.

Transformative Shifts in Clinical Trial Imaging

The clinical trial imaging environment is undergoing transformative shifts driven by precision medicine, digital trial infrastructure, and the expansion of complex therapeutic research. Imaging endpoints are increasingly incorporated into adaptive trial designs, basket trials, umbrella trials, and targeted therapy studies, particularly where anatomical, functional, or molecular imaging can help identify patient subgroups and quantify treatment response. In oncology, standardized response criteria and lesion measurement workflows remain central, while neurodegenerative disease research increasingly relies on volumetric MRI, amyloid and tau PET, and other biomarker-based imaging approaches.

Operationally, the sector is moving toward cloud-based image exchange, automated de-identification, remote site qualification, centralized quality control, and real-time query management. These capabilities are reducing delays associated with image transfer, site variability, and incomplete datasets. At the same time, decentralized and hybrid trial models are increasing demand for imaging networks that can support consistent protocol execution across academic medical centers, community hospitals, specialist imaging sites, and mobile or satellite facilities.

Scientific and regulatory standards are also advancing. Good Clinical Practice, data integrity principles, imaging charter governance, standardized acquisition parameters, and independent central review remain critical to ensuring that imaging-derived evidence is reliable. The convergence of imaging biomarkers, electronic clinical outcome assessments, electronic data capture, and laboratory datasets is creating a more integrated evidence ecosystem, enabling trial teams to connect imaging findings with clinical outcomes, genomics, pathology, and safety data.

Cumulative Impact of AI in Clinical Trial Imaging

Artificial intelligence is having a cumulative impact on clinical trial imaging by improving efficiency, consistency, and analytical depth across the imaging workflow. AI-enabled tools are being applied to image quality assessment, organ and lesion segmentation, anatomical registration, radiomics feature extraction, workflow triage, missing-data detection, and longitudinal change analysis. These applications can reduce manual burden, support standardized measurements, and help identify imaging patterns that may not be apparent through conventional visual interpretation alone.

In clinical development, AI is increasingly relevant for patient selection, endpoint refinement, and response monitoring. Machine learning models can assist in identifying phenotypic patterns from multimodal imaging datasets and may support enrichment strategies where imaging biomarkers are linked to disease progression or treatment sensitivity. In therapeutic areas such as oncology, neurology, cardiology, and inflammatory disease, AI-driven quantitative imaging has the potential to improve reproducibility when deployed under validated, controlled, and well-documented conditions.

However, adoption depends on rigorous governance. Algorithm validation, dataset diversity, bias assessment, explainability, version control, cybersecurity, and regulatory transparency are essential for responsible implementation. Clinical trial stakeholders must ensure that AI tools are fit for purpose, locked or appropriately controlled when used for endpoint generation, and supported by documented performance evidence. The most effective deployments combine automation with expert oversight, enabling AI to strengthen-not replace-the scientific and clinical judgment required in regulated clinical research.

Key Regional Insights for Clinical Trial Imaging

Asia-Pacific is strengthening its role in clinical trial imaging through expanding clinical research activity, growing hospital infrastructure, and increasing adoption of advanced diagnostic modalities across China, India, Japan, South Korea, Australia, and Southeast Asia. The region benefits from large patient populations, disease diversity, and rising investment in oncology, cardiology, and neurological research. Imaging operations in Asia-Pacific often require careful protocol harmonization because site capabilities, scanner availability, accreditation levels, and data transfer infrastructure can vary substantially across markets.

North America remains a highly mature environment for clinical trial imaging due to its dense network of academic medical centers, specialist imaging facilities, experienced investigators, and established regulatory pathways. The United States and Canada have strong capabilities in independent central review, imaging biomarker research, advanced MRI and PET applications, and digital trial technologies. North American trial sites are frequently involved in early-phase, pivotal, and complex imaging-intensive studies, particularly in oncology, neurology, rare diseases, and advanced therapeutics.

Latin America is gaining relevance as sponsors seek broader patient access, diverse populations, and experienced clinical research sites in countries such as Brazil and Mexico. Imaging-based trials in the region are supported by major urban healthcare centers with advanced radiology capabilities, although operational planning must account for differences in infrastructure, ethics review timelines, image transfer logistics, and protocol training needs.

Europe is characterized by strong clinical research governance, mature healthcare systems, and extensive expertise in radiology, nuclear medicine, and imaging biomarker standardization. Countries including Germany, France, the United Kingdom, Italy, and Spain contribute to multicenter imaging trials across oncology, cardiovascular disease, inflammatory disorders, and neurodegeneration. European operations must align with stringent data protection requirements, cross-border data transfer rules, and country-specific trial authorization processes.

The Middle East is developing as a clinical trial imaging destination through investments in tertiary care, oncology centers, digital health infrastructure, and specialized diagnostic services, particularly in Gulf countries. The region's strengths include modern hospital systems in key urban centers and increasing participation in multinational research, while success depends on site selection, imaging protocol training, and alignment with local regulatory and ethics frameworks.

Africa presents emerging opportunities for clinical trial imaging, particularly where academic hospitals and regional centers support infectious disease, oncology, cardiovascular, and public health research. Imaging capabilities vary widely across the continent, making feasibility assessment, equipment validation, reader support, data connectivity, and capacity-building essential. Well-planned imaging operations can help improve research inclusion while supporting reliable evidence generation in underrepresented populations.

Key Group Insights for Clinical Trial Imaging

ASEAN is becoming increasingly important for clinical trial imaging as countries across Southeast Asia invest in healthcare modernization, cancer care, and digital research infrastructure. The region offers access to diverse patient populations and growing investigator experience, but imaging operations must address variability in scanner specifications, site accreditation, radiology workforce availability, and cross-border data management practices.

The GCC demonstrates strong potential for imaging-enabled clinical research due to investments in advanced hospitals, national health strategies, oncology programs, and medical technology adoption. Imaging trials in GCC countries benefit from modern diagnostic platforms in leading centers, while sponsors must account for ethics requirements, data residency considerations, local patient recruitment dynamics, and the need for standardized reader and technologist training.

The European Union supports clinical trial imaging through harmonized clinical trial regulation, established data protection frameworks, and deep expertise in imaging science. EU-based studies benefit from high-quality radiology networks, nuclear medicine capabilities, and academic collaboration, but operational planning must carefully manage General Data Protection Regulation compliance, multinational contracting, language requirements, and country-level implementation timelines.

BRICS countries are influential in the global clinical trial imaging ecosystem because they combine large patient populations with expanding research infrastructure and increasing investment in healthcare technology. Brazil, Russia, India, China, and South Africa each present distinct regulatory, operational, and imaging-capability profiles. For sponsors, BRICS participation can improve population diversity and recruitment access when supported by strong site feasibility, imaging quality assurance, and centralized review processes.

The G7 represents a highly advanced clinical research environment with robust regulatory systems, experienced investigators, sophisticated imaging facilities, and strong adoption of digital trial platforms. G7 countries are often central to complex imaging-intensive protocols involving advanced MRI, PET, CT, radiomics, artificial intelligence, and biomarker-driven endpoints. Their strengths lie in scientific depth and regulatory maturity, although costs, contracting timelines, and data governance requirements require disciplined operational management.

NATO member countries include many of the world's most developed clinical research environments across North America and Europe. For clinical trial imaging, this group offers strong hospital networks, established research ethics systems, and high-quality imaging infrastructure. Multinational imaging studies across NATO countries benefit from technical maturity and investigator experience, while requiring alignment across privacy rules, healthcare systems, site workflows, and imaging data transfer standards.

Key Country Insights for Clinical Trial Imaging

The United States is a leading hub for clinical trial imaging, supported by extensive academic research networks, advanced radiology and nuclear medicine infrastructure, and broad experience with regulatory submissions involving imaging endpoints. Canada contributes strong clinical research governance, high-quality hospital systems, and expertise in oncology, neurology, and cardiovascular imaging. Mexico is gaining traction in multinational trials through large urban medical centers, improving research capacity, and access to treatment-naive or diverse patient populations.

Brazil is one of Latin America's most important clinical research markets, with major hospitals supporting imaging-based oncology, cardiology, infectious disease, and rare disease studies. The United Kingdom maintains strong capabilities in imaging science, central review expertise, and biomarker-driven research, supported by integrated health data resources and established clinical trial networks. Germany is recognized for advanced medical imaging infrastructure, radiology research, and participation in complex multicenter trials, while France contributes strong nuclear medicine, oncology, neurology, and public-sector research capabilities.

Russia has historically supported multinational clinical studies through large patient pools and specialist medical institutions, although geopolitical, regulatory, and operational factors require careful assessment. Italy and Spain remain important European contributors to imaging trials, particularly in oncology, inflammatory disease, cardiology, and neurological disorders, supported by experienced investigators and advanced hospital-based imaging services.

China is increasingly central to clinical trial imaging due to large patient populations, rapid expansion of advanced hospitals, and growing domestic and international research activity. India offers significant recruitment potential and expanding diagnostic imaging capacity, although site qualification and protocol standardization are essential to manage infrastructure variability. Japan provides high-quality imaging infrastructure, strong regulatory discipline, and deep expertise in oncology, neurology, and advanced diagnostics. Australia is valued for high-quality clinical trial execution, experienced investigators, and alignment with international research standards. South Korea has become a highly capable imaging trial environment, supported by advanced hospital systems, digital health adoption, oncology expertise, and strong execution in complex multicenter research.

Actionable Recommendations for Imaging Leaders

Industry leaders should embed imaging strategy early in clinical trial design rather than treating it as a downstream operational component. Early planning should define fit-for-purpose imaging endpoints, modality selection, acquisition parameters, reader models, adjudication rules, quality control workflows, and statistical alignment with clinical objectives. Imaging charters should be clear, operationally practical, and consistent with regulatory expectations.

Sponsors and research teams should prioritize site feasibility based on imaging capability, scanner specifications, technologist experience, connectivity, prior trial performance, and ability to comply with protocol-specific acquisition requirements. Standardized training for radiologists, nuclear medicine physicians, technologists, and site coordinators is essential to reduce variability. Centralized quality control and rapid feedback loops should be implemented to identify image acquisition issues before they compromise endpoint integrity.

Organizations adopting artificial intelligence should establish validation frameworks, audit trails, cybersecurity controls, human oversight, and clear documentation of algorithm use. Imaging data should be integrated with clinical, laboratory, genomic, pathology, and patient-reported outcome datasets through interoperable and compliant platforms. Leaders should also build regional operating models that account for privacy rules, data transfer restrictions, language requirements, and site-level infrastructure differences. The strongest clinical trial imaging programs will combine scientific rigor, operational discipline, digital scalability, and regulatory transparency.

Research Methodology for Clinical Trial Imaging

A robust research methodology for clinical trial imaging analysis should combine secondary research, expert validation, regulatory review, and structured qualitative assessment. Secondary research should include peer-reviewed medical literature, clinical trial registries, regulatory guidance documents, public health agency publications, imaging society standards, clinical endpoint criteria, and publicly available information on modality adoption, trial design practices, and therapeutic area trends.

Primary validation should involve discussions with clinical trial imaging specialists, radiologists, nuclear medicine experts, clinical operations leaders, biostatisticians, regulatory professionals, and technology stakeholders. These interviews help verify operational realities such as site readiness, imaging charter implementation, quality control challenges, central review models, artificial intelligence adoption, and regional data governance considerations.

The methodology should avoid unsupported extrapolation and should not rely on market sizing or forecasting. Instead, it should emphasize evidence-based interpretation of regulatory developments, technology adoption patterns, trial design evolution, regional infrastructure maturity, and clinical use cases. Data triangulation across scientific publications, regulatory sources, trial registries, and expert input helps ensure that insights are reliable, current, and relevant to decision-makers in imaging-enabled clinical research.

Conclusion: Imaging as a Strategic Evidence Engine

Clinical trial imaging is increasingly central to modern drug and device development because it supports objective assessment, biomarker discovery, patient stratification, and longitudinal monitoring across complex therapeutic areas. The field is advancing through standardized imaging protocols, centralized review, digital image exchange, quantitative analytics, and artificial intelligence-enabled workflows. These capabilities are improving data consistency and helping clinical teams generate more reliable evidence across global trial networks.

Regional and country-level differences in infrastructure, regulation, workforce expertise, and data governance remain critical considerations. Successful imaging programs require early strategic planning, rigorous quality control, validated technology, experienced site networks, and clear alignment between scientific objectives and operational execution. As precision medicine and biomarker-driven research continue to expand, clinical trial imaging will remain a vital component of high-quality, compliant, and patient-centered clinical development.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Clinical Trial Imaging Market, by Offerings

  • 7.1. Introduction
  • 7.2. Services
    • 7.2.1. Operational Imaging Services
    • 7.2.2. Read Analysis Services
    • 7.2.3. System & Technical Support Services
    • 7.2.4. Trial Design & Consulting Services
  • 7.3. Software
  • 7.4. Hardware

8. Clinical Trial Imaging Market, by Modality

  • 8.1. Introduction
  • 8.2. Computed Tomography
  • 8.3. Echocardiography
  • 8.4. Magnetic Resonance Imaging
  • 8.5. Positron Emission Tomography
  • 8.6. Ultrasound
  • 8.7. X-Ray

9. Clinical Trial Imaging Market, by End-User

  • 9.1. Introduction
  • 9.2. Academic & Government Research Institutes
  • 9.3. Biotechnology Companies
  • 9.4. Contract Research Organizations
  • 9.5. Pharmaceutical Companies

10. Clinical Trial Imaging Market, by Therapeutic area

  • 10.1. Introduction
  • 10.2. Endocrinology
  • 10.3. Immunological Disorder
  • 10.4. Infectious Diseases
  • 10.5. Neurology
  • 10.6. Oncology

11. Clinical Trial Imaging Market, by Region

  • 11.1. Asia-Pacific
  • 11.2. North America
  • 11.3. Latin America
  • 11.4. Europe
  • 11.5. Middle East
  • 11.6. Africa

12. Clinical Trial Imaging Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Clinical Trial Imaging Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2025
  • 14.2. FPNV Positioning Matrix, 2025
  • 14.3. Market Concentration Analysis, 2025
    • 14.3.1. Concentration Ratio (CR)
    • 14.3.2. Herfindahl Hirschman Index (HHI)
  • 14.4. Recent Developments & Impact Analysis, 2025
  • 14.5. Product Portfolio Analysis, 2025
  • 14.6. Benchmarking Analysis, 2025

15. Company Profiles

  • 15.1. Alimentiv Inc.
  • 15.2. Anagram 4 Clinical Trials
  • 15.3. Biospective Inc.
  • 15.4. BioTelemetry, Inc.
  • 15.5. Boston Imaging Core Lab LLC
  • 15.6. Cardiovascular Imaging Technologies LLC
  • 15.7. Clario
  • 15.8. GE HealthCare Technologies Inc.
  • 15.9. Icon PLC
  • 15.10. Image Analysis Ltd
  • 15.11. Image Core Lab Private Limited
  • 15.12. Imaging Endpoints II LLC
  • 15.13. Invicro, LLC
  • 15.14. Ixico PLC
  • 15.15. Median Technologies
  • 15.16. Medical Metrics Inc. by Catalent, Inc.
  • 15.17. Medidata by Dassault Systemes
  • 15.18. Medpace, Inc.
  • 15.19. Micron Inc.
  • 15.20. Mint Medical GmbH
  • 15.21. Navitas Life Sciences
  • 15.22. Parexel International Corporation
  • 15.23. Perceptive Informatics LLC
  • 15.24. Perspectum Ltd
  • 15.25. Prism Clinical Imaging, Inc.
  • 15.26. ProScan Imaging LLC
  • 15.27. Quotient Sciences Limited
  • 15.28. Radiant Sage LLC
  • 15.29. Resonance Health Ltd.
  • 15.30. Voiant Clinical
  • 15.31. WCG Clinical, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CLINICAL TRIAL IMAGING MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL CLINICAL TRIAL IMAGING MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL CLINICAL TRIAL IMAGING MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL CLINICAL TRIAL IMAGING MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY OFFERINGS, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY OFFERINGS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL CLINICAL TRIAL IMAGING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 21. GLOBAL CLINICAL TRIAL IMAGING MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL CLINICAL TRIAL IMAGING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL OPERATIONAL IMAGING SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL OPERATIONAL IMAGING SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL OPERATIONAL IMAGING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL READ ANALYSIS SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL READ ANALYSIS SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL READ ANALYSIS SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL SYSTEM & TECHNICAL SUPPORT SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL SYSTEM & TECHNICAL SUPPORT SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL SYSTEM & TECHNICAL SUPPORT SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL TRIAL DESIGN & CONSULTING SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL TRIAL DESIGN & CONSULTING SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL TRIAL DESIGN & CONSULTING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL SOFTWARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL SOFTWARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL SOFTWARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL HARDWARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL HARDWARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL HARDWARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL COMPUTED TOMOGRAPHY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL COMPUTED TOMOGRAPHY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL COMPUTED TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ECHOCARDIOGRAPHY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ECHOCARDIOGRAPHY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ECHOCARDIOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MAGNETIC RESONANCE IMAGING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MAGNETIC RESONANCE IMAGING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MAGNETIC RESONANCE IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ULTRASOUND MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ULTRASOUND MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ULTRASOUND MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL X-RAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL X-RAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL X-RAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ACADEMIC & GOVERNMENT RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ACADEMIC & GOVERNMENT RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ACADEMIC & GOVERNMENT RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ENDOCRINOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ENDOCRINOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ENDOCRINOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL IMMUNOLOGICAL DISORDER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL IMMUNOLOGICAL DISORDER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL IMMUNOLOGICAL DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEUROLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NEUROLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEUROLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE CLINICAL TRIAL IMAGING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE CLINICAL TRIAL IMAGING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 98. MIDDLE EAST CLINICAL TRIAL IMAGING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. MIDDLE EAST CLINICAL TRIAL IMAGING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 100. MIDDLE EAST CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 103. MIDDLE EAST CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 104. AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 106. AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 107. AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN CLINICAL TRIAL IMAGING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN CLINICAL TRIAL IMAGING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 113. ASEAN CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 115. ASEAN CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 116. ASEAN CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 117. GCC CLINICAL TRIAL IMAGING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GCC CLINICAL TRIAL IMAGING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 119. GCC CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 120. GCC CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 121. GCC CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 122. GCC CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPEAN UNION CLINICAL TRIAL IMAGING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPEAN UNION CLINICAL TRIAL IMAGING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPEAN UNION CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPEAN UNION CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPEAN UNION CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 129. BRICS CLINICAL TRIAL IMAGING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. BRICS CLINICAL TRIAL IMAGING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 131. BRICS CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 133. BRICS CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 134. BRICS CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 135. G7 CLINICAL TRIAL IMAGING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. G7 CLINICAL TRIAL IMAGING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 137. G7 CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 138. G7 CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 139. G7 CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 140. G7 CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 141. NATO CLINICAL TRIAL IMAGING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. NATO CLINICAL TRIAL IMAGING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 143. NATO CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 144. NATO CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 145. NATO CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 146. NATO CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. UNITED STATES CLINICAL TRIAL IMAGING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 149. UNITED STATES CLINICAL TRIAL IMAGING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 150. UNITED STATES CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 151. UNITED STATES CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 152. UNITED STATES CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 153. UNITED STATES CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 154. CANADA CLINICAL TRIAL IMAGING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 155. CANADA CLINICAL TRIAL IMAGING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 156. CANADA CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 157. CANADA CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 158. CANADA CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 159. CANADA CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 160. MEXICO CLINICAL TRIAL IMAGING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 161. MEXICO CLINICAL TRIAL IMAGING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 162. MEXICO CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 163. MEXICO CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 164. MEXICO CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 165. MEXICO CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 166. BRAZIL CLINICAL TRIAL IMAGING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 167. BRAZIL CLINICAL TRIAL IMAGING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 168. BRAZIL CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 169. BRAZIL CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 170. BRAZIL CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 171. BRAZIL CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 172. UNITED KINGDOM CLINICAL TRIAL IMAGING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 173. UNITED KINGDOM CLINICAL TRIAL IMAGING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 174. UNITED KINGDOM CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED KINGDOM CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 176. UNITED KINGDOM CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 177. UNITED KINGDOM CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 178. GERMANY CLINICAL TRIAL IMAGING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 179. GERMANY CLINICAL TRIAL IMAGING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 180. GERMANY CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 181. GERMANY CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 182. GERMANY CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 183. GERMANY CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 184. FRANCE CLINICAL TRIAL IMAGING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 185. FRANCE CLINICAL TRIAL IMAGING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 186. FRANCE CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 187. FRANCE CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 188. FRANCE CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 189. FRANCE CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 190. RUSSIA CLINICAL TRIAL IMAGING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 191. RUSSIA CLINICAL TRIAL IMAGING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 192. RUSSIA CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 193. RUSSIA CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 194. RUSSIA CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 195. RUSSIA CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 196. ITALY CLINICAL TRIAL IMAGING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 197. ITALY CLINICAL TRIAL IMAGING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 198. ITALY CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 199. ITALY CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 200. ITALY CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 201. ITALY CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 202. SPAIN CLINICAL TRIAL IMAGING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 203. SPAIN CLINICAL TRIAL IMAGING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 204. SPAIN CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 205. SPAIN CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 206. SPAIN CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 207. SPAIN CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 208. CHINA CLINICAL TRIAL IMAGING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 209. CHINA CLINICAL TRIAL IMAGING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 210. CHINA CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 214. INDIA CLINICAL TRIAL IMAGING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 215. INDIA CLINICAL TRIAL IMAGING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 216. INDIA CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 217. INDIA CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 218. INDIA CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 219. INDIA CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 220. JAPAN CLINICAL TRIAL IMAGING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 221. JAPAN CLINICAL TRIAL IMAGING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 222. JAPAN CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 223. JAPAN CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 224. JAPAN CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 225. JAPAN CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 226. AUSTRALIA CLINICAL TRIAL IMAGING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 227. AUSTRALIA CLINICAL TRIAL IMAGING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 228. AUSTRALIA CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 229. AUSTRALIA CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 230. AUSTRALIA CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 231. AUSTRALIA CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 232. SOUTH KOREA CLINICAL TRIAL IMAGING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 233. SOUTH KOREA CLINICAL TRIAL IMAGING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 234. SOUTH KOREA CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 235. SOUTH KOREA CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 236. SOUTH KOREA CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 237. SOUTH KOREA CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 238. GLOBAL CLINICAL TRIAL IMAGING MARKET SHARE, BY KEY PLAYER, 2025
  • TABLE 239. GLOBAL CLINICAL TRIAL IMAGING MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025